Clinical trials: Buprenorphine
Opioid-Related Disorders
Buprenorphine Dosing Interval - 5
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
- Trial name
- NCT00000209
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-related Disorders
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
The purpose of this study is to compare the presence, degree, time course and profile of opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine or buprenorphine/naloxone in persons with active…
- Trial name
- NCT00637000
- Testing
- Buprenorphine soluble film, Buprenorphine/naloxone film strip
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Indivior Inc.
Opioid-use Disorder
Emergency Department-Initiated Buprenorphine Validation Network Trial
This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S.
- Trial name
- NCT04225598
- Testing
- CAM2038, Buprenorphine Sublingual Product
- Where
- 35 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Yale University
Opioid-use Disorder
Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment
A global and integrative treatment of opioid-use disorders (OUD) with opiate maintenance therapy (OMT) and psychosocial interventions is recommended by all current guidelines.
- Trial name
- TOPAZE (NCT03729388)
- Testing
- Prognosis factor associated with good outcome.
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Opioid Use Disorder
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for…
- Trial name
- BIPOD-Out (NCT06067737)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Post Traumatic Stress Disorder, Opioid-use Disorder
Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans
The overall objective of the proposed study is to determine if lofexidine (LFX) as an adjunct to buprenorphine (BUP) treatment improves symptoms of both opioid use disorder (OUD) and Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT04360681
- Testing
- Lofexidine
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Chronic Pain
Effectiveness of Buprenorphine/Naloxone
Long-term use of opioids for chronic pain is a growing health and social problem, mainly because of the risk of dependence. Buprenorphine/naloxone is used as substitution therapy for opioid dependence.
- Trial name
- NCT02882412
- Testing
- observational
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Cancer
Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain
Buprenorphine transdermal patch is newly available in Taiwan in June 2017, the trade name is Transtec, and the available dosages are 35 μg/h and 52.5 μg/h.
- Trial name
- SOOTHE (NCT04315831)
- Testing
- Transdermal Buprenorphine
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Opioid Use Disorder, HIV Infections
Buprenorphine Integration Research and Community Health
The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia.
- Conditions
- Opioid Use Disorder, HIV Infections, Hepatitis C
- Trial name
- BIRCH (NCT05668780)
- Testing
- NIATx Coaching
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Refractory Major Depressive Disorder
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
- Trial name
- NCT03610048
- Testing
- ALKS 5461
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Alkermes, Inc.
Opioid Use Disorder
Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine
This study aims to develop and pilot test a patient decision aid (PtDA) for emergency department (ED)-initiated buprenorphine treatment for opioid use disorder (OUD).
- Trial name
- NCT07278518
- Testing
- Patient Decision Aid for Opioid Use Disorder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Opioid-Related Disorders
Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs.
- Trial name
- NCT00000320
- Testing
- Buprenorphine formulation: liquid vs. tablet
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders
Trial of Adherence App for Buprenorphine Treatment (TAAB) Study
The purpose of this study is to pilot test a smartphone application that allows video-based directly observed therapy for participants receiving buprenorphine treatment for opioid use disorder in office-based settings.
- Trial name
- NCT03779997
- Testing
- Video-based DOT Application
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Washington
Chronic Pain
Dronabinol Opioid Sparing Evaluation (DOSE) Trial
This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients…
- Trial name
- NCT03766269
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Daisy Pharma Opioid Venture, LLC
Opioid-related Disorders, Buprenorphine
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive.
- Conditions
- Opioid-related Disorders, Buprenorphine, HIV, Cognition
- Trial name
- NCT01108679
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Addiction
To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine
A team of researchers from the University of Wisconsin-Madison College of Engineering and Oregon Health \& Science University will test whether clinician training and the use of organizational change strategies are sufficient for…
- Trial name
- NCT01702142
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy
A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone
A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg Buprenorphine/Naloxone. NIDA Contract No. HHSN271200577414C
- Trial name
- NCT00880841
- Testing
- Buprenorphine / Naloxone
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NanoSHIFT LLC
Opioid Use Disorder
Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder
This is a single-center, randomized, open-label, single-dose, parallel-group study which will enroll and randomize approximately 48 subjects (to achieve 36 completers) with opioid use disorder (OUD) who are seeking treatment for…
- Trial name
- NCT02559973
- Testing
- RBP-6000, SUBOXONE Sublingual Film
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder, Opioid Use Disorder, Severe
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
- Trial name
- BISTRO (NCT07631598)
- Testing
- Standard of Care Referral, Low Threshold Buprenorphine
- Where
- 8 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Opioid-Related Disorders
Buprenorphine Combination Tablet Feasibility - 1
The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial…
- Trial name
- NCT00000298
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)